d new pipeline opportunities. We see positive surprise potential on these programmes, particularly if clinical data supports attractive pricing for SHP621 (est. 150k patients in the US alone, many of whom have few effective treatments). Related DB Research: Shire: Headline HAVEN 3 data incrementally bette